ISO 9001: 2015 CERTIFIED COMPANY

Ref. No. ACME /CA/CS/2021/0125

14 November 2021

The Chairman

Bangladesh Securities and Exchange Commission Securities Commission Bhaban, E-C/6, Agargaon, Sher-e-Bangla Nagar Administrative Area, Dhaka-1207.

Subject: Audited Status Report on utilization of Initial Public Offering Proceeds for the Month ended 31 October 2021 of The ACME Laboratories Ltd.

Dear Sir,

In compliance with the clause 3 & 4 of Part-C of the Letter of Consent, vide no. BSEC/CI/BB-03/2014/143; dated: 15 March 2016 accorded by your esteemed organization, we are pleased to enclose herewith the Audited Status Report (as per revised format) on utilization of Initial Public Offering Proceeds for the Month ended 31 October 2021 of The ACME Laboratories Ltd. duly authenticated by the Board of Directors in its 136th Meeting held on 11 November 2021 for your kind perusal and record please.

Thanking you and assuring of our best attention for all the time to come.

Mizanur Rahman Sinha

Managing Director

Enclosure: As stated above

Copy to: 01. The Managing Director, Dhaka Stock Exchange Limited

lecurities & Exchange Compaission

02. The Managing Director, Chittagong Stock Exchange Limited

03. The Chief Executive Officer, ICB Capital Management Limited

Corporate Office: Court de la ACME

1/4 Kallayanpur, Mirpur Road Dhaka-1207, Bangladesh. Phone: +88-02-9004194-6

Fax : +88-02-9016872 E-mail : headoffice@acmeglobal.com www.acmeglobal.com

Plant:

Dhamrai, Dhaka, Bangladesh.

Phone: +88-02-7730881-2 +88-02-7730816-7, 7730142

Fax : +88-02-7730141 E-mail : plant@acmeglobal.com

Auditors' Report

Name of Client

The ACME Laboratories Ltd.

Utilization of IPO Proceeds For the Month ended 31 October 2021







Registered Office: AHSANDELL, 2/A, Mymensingh Road (2nd Floor), Shahbag, Dhaka-1000, Bangladesh.

Tel: +08802-966-0944, +8802-966-5095, Cell: +8801711-106302, +8801534-130750.

E-mail: pinaki_co@yahoo.com website: www.pinaki.com.bd







AUDITORS' REPORT

OH

Utilization of IPO Proceeds

have audited the annexed Statement of Initial Public Offering (IPO) Proceeds Utilization of The ME Laboratories Ltd. for the month ended 31 October 2021.

inagement's Responsibility for the IPO proceeds Utilization

magement is responsible for the preparation and fair presentation of these IPO proceeds utilization tement in accordance with Bangladesh Securities and Exchange Commission Rules 1987, Condition I down in clause3 & 4 of PART-C of consent letter # BSEC/CI/BB-03/2014/143, Dated March 15, 16 and other applicable laws and regulations.

iditor's Responsibility

responsibility is to express an independent opinion on these Initial Public Offering (IPO) proceeds fization statement based on our audit. We conducted our audit in accordance with International andards on Auditing (ISA), Bangladesh Securities and Exchange Commission Rules 1987, addition laid down in clause 3 & 4 of PART-C of consent letter # BSEC/CI/BB-03/2014/143, Dated such 15, 2016 and other applicable laws and regulations.

believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for raudit opinion.

inion

cur Opinion, the Statement of Initial Public Offering (IPO) Proceeds Utilization, Prepared in perdance with Bangladesh Securities and Exchange Commission Rules 1987 and Condition laid an in clause 3 & 4 of PART-C of consent letter # BSEC/CI/BB-03/2014/143, Dated March 15, life gives a true and fair view of the statement for the month ended 31 October 2021 and comply with resolution of 42nd and 44th AGM of the company.

per TOR, We draw attention to the following matter:

 The Company has started commercial operation of Steroid and Hormone project in the month of June 2019, which has been completed within the time limit approved by the shareholders in its 42nd AGM. Total project cost of BDT 1,660,591,186 is generated from the IPO fund.







- The Company has started commercial operation of Penicillin project in the month of June 2019, which has been completed within the time limit approved by the shareholders in its 42nd AGM. Total project cost of BDT 400,000,000 is generated from the IPO fund.
- The Company has also utilized accumulative amount of Tk.579,326,015 up to 31 October 2021 in respect of API Project. During the month of October 2021, an amount of Tk.22,163,094 has been utilized out of IPO fund in respect of Active Pharmaceuticals Ingredients (API) Project.

also state that:

- IPO proceeds of Steroid and Hormone Projects well as Penicillin Project have been utilized for the purposes as specified in the resolution of 42nd AGM of the company;
- b) IPO proceeds have been utilized in line with the conditions of the BSEC's consent letter for the IPO;
- API project, for which IPO fund was raised, will be completed within the time frame as specified in the resolution of 42nd AGM of the company.
- Utilization of IPO proceeds is accurate for the purpose of the company as mentioned in the resolution of 42nd and 44th AGM of the company.
- Audit statement has been made on verification of all necessary documents/papers/vouchers in support of utilization of IPO proceeds making reconciliation with bank statements.

te: 11 November 2021

Pinaki Das, FCA
Senior Partner
ICAB Enrol. No: 151
Pinaki & Company
Chartered Accountants



WHITE OR STREETING OF 1PLY PRINCES





7,514,825

Nagere Afra

(Nagina Afzai Sinha)

(Mizanur Rahman Sinha)

(Tasneem Sinha)

Director

Dated: 11 November 2021

Dhaka

Un-Utilized IPO Proceeds with interest income in BDT

On Behalf of Board

Interest on IPD Proceeds in BOT (from FDR & SND)

÷

Managing Director

Chartered Accountants

been approved in 12nd and 46th AGM avon 6 December 2018 & 10 December Oldzation Proceedy Phaki and Company, Chartered Reservangement of Utilization Plan has certified by MVs. 2020 pest IIIO 0.65% 96000 0.00% 0.00% 0.00% 5600.0 0.00% 2000 0.007% 0.00% 20000 2000 30000 0.00% 0.00% 0.00% 9600'0 Total Oritical Stilling Total on attitud 26,806,530 26,806,530 26,806,530 4,068,209,071 99.35% 300.001 985.28 68,291,870 100.00% 100.001 100.00% 100,00% 100.001 9,000,0 0.00% 0.00% 3,360,000,000,000 100.00% 100,00% 100 00% 100.001 0.00% 579,326,015 95,58% 9,570,901 854,934,678 000'006'006 21,986,000 5,000,000 1,700,000 79,768,602 1,420,250 5,000,000 400,000,000 953,700,000 1,660,591,186 142,922,303 146,345,797 21,641,545 2,901,503 579,326,015 BITT COLLEGE SECRET SECRET OF PARISH LINESCOPE CONSERVATION (MAS) 22,163,094 22,163,094 22,163,094 Chrima the 557,162,921 557,162,921 4,046,045,977 400,000,000 1,360,000,000 68,291,870 146,345,797 21,641,545 2,901,503 1,420,250 5,000,000 114,934,878 000,000,000 151,700,000 21,986,000 5,000,000 1,290,000 9,870,308 981,182,099,1 142,922,303 79,768,602 For the felenth of October 3033 1,350,000,000 68,291,870 4,095,015,601 1,420,250 5,000,000 400,000,000 606,132,545 606,132,545 1,700,000 9,870,308 1,660,591,186 142,922,303 79,768,602 146,345,797 21,641,545 2,901,503 21,986,000 3,000,000 Amount on per 154,534,878 013,3600,000 111,700,000 44th AGN! OCT & 1004, 0000, 010 (Macanyark arrespond 1,360,000,000 68,291,870 9,870,308 606,132,545 4,095,015,601 281,168,050,1 400,000,000 355,637,304 250,495,241 21,5000,000 5,000,000 1,700,000 142,922,303 79,768,602 146,345,797 21,641,545 2,901,503 1,420,250 5,000,000 The ACM Laboratories Md. Amount or per 334,954,878 933,900,000 353,700,000 ASMI AGAR LEApoid 2016 to 21 April 2016 As attacked in time from collament 1,360,000,000 4,541,520,162 68,291,870 400,000,000 1,355,228,292 1,358,000,000 132,299,520 117,154,000 20,582,700 3,000,000 5,963,780 5,000,000 347,860,000 493,000,000 409,400,000 38,500,000 3,000,000 5,000,000 26,300,000 13,200,000 116,000,000 23,635,200 12,917,600 26,915,492 Amount or per 115,800,000 500,000,000 119,600,000 000/005/64 23 April 2016 40th ALINE Initial Working Capital COAT Breeskallown Mathinery & Equipt Machinery & David Dvil Construction Machinery & Equi Civil Construction Consultancy fee Consultancy fee Synsideancy fee Contentiencies Contengencies Contemperaties Warehouse Warehouse Sub Fotal Sub Total Sub Total take Date of Full Unitertain of IPO Fund as per 40th A0M/A0sul AtM Vehicle Vehicle Vehicle Utility As per 40th As per 42nd AGM AGM Within fare Within June Within June 2013 2019 2022 N/A N/A Within the month of March 2018 (All Businesses Assessed (NOTS of capital sensed through PCS Within 2-3 years after getting permission Ministry of Industries Within 2 powers of from the hand, i.e. N/A N/A Repayment of Bank Borrowing at 40th AGM Acrive Pharmaceuticals Purpuse mentioned in the 40th AGNI/42nd Name of the Company Steroid and Hormone Ingredients (API) Date of Close of Subscript Peniollin Project Proceeds Necessing Date Project AGM PO Expenses Total

d Office: AHSANDELL, 2/A, Mymensingh Road (2nd Floor), Shahbag, Dhaka-1000, Bangladesh. 448-63092, +8802-448-63093 & +8802-448-63094, Cell: +8801317-201224, +881534-130750. E-mail: pinaki_co@yahoo.com, info@pinakicabd.com website: www.pinaki.com.bd